Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Lutetium Lu 177 dotatate may be m

Trial Details

NCT ID
NCT04665739
Phase
PHASE2
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Biospecimen Collection
  • Computed Tomography
  • Everolimus
  • Fludeoxyglucose F-18
  • Lutetium Lu 177 Dotatate
  • Magnetic Resonance Imaging
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Loma Linda, California, United States|34.04835,-117.26115
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • PRE-REGISTRATION: Pathologic Documentation: Well- or moderately-differentiated neuroendocrine tumor(s) of bronchial origin (i.e. carcinoid) as asse…
  • The pathology report must state ONE of the following:
  • Well- or moderately-differentiated neuroendocrine tumor,
  • Low- or intermediate-grade neuroendocrine tumor, or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →